Tianjin Development (00882.HK) subsidiary Lifecare Pharmaceutical expects its net profit attributable to shareholders in the first half of the year to increase by 222.42% to 246.85% year-on-year, reaching 330 million to 355 million yuan.

China Fortune Financial APP news, Tianjin Development (00882.HK) announced that its indirectly held non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical) is expected to achieve a net profit attributable to the shareholders of the listed company in the first half of 2025 of 3.3 billion yuan to 3.55 billion yuan, a year-on-year increase of 222.42%-246.85%; the net profit after deducting non-recurring gains and losses is expected to be 1 billion yuan to 1.15 billion yuan, a year-on-year increase of 0.83%-15.95%.